Learn how protein-level evidence can augment or replace genomic inference at critical decision points in oncology drug development.
Expert Q&A on how tumor protein profiling can de-risk oncology programs, delivering novel insights not inferred by genomics.
Query target protein expression across 15+ normal human tissues to establish baseline biological context for drug development.
A unified system for multi-dimensional measurement of functional biology across 12,000+ proteins in human tumors.
Multi-dimensional proteomic characterization across 15+ normal human tissues to de-risk target selection.
How converging innovation cycles have transformed mass spectrometry into a scalable platform for drug development.
How Sapient's multi-omics workflows helped identify an anti-inflammatory signature in early-passage MSC-derived exosomes.
Quantify specific proteins with sequence-confirmed accuracy – without the antibody limitations of ELISA.
Directly measuring the layers of functional tumor biology that shape how a tumor behaves and responds to treatment.
Introducing SurfaceSeek™, SignalingSeek™, ImmuneSeek™, and ResistanceSeek™ – optimized for fresh & FFPE human tumors.
Directly measure proteins that are truly accessible on the tumor cell surface, enabling confident target identification.
Directly measure phosphorylation-driven signaling activity in human tumors to characterize functional pathway activation.
